Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons

Alessandro Busca, Livio Pagano

Research output: Contribution to journalArticle

Abstract

Introduction: Along with new diagnostic options, comes the recent development of novel antifungal agents that expanded the spectrum of activity over traditional treatments contributing to the successful management of fungal diseases. Nevertheless, invasive fungal infections (IFI) represent a major hindrance to the favorable outcome of patients with hematologic malignancies. According to these observations, an appropriate prevention of IFI occurring in hematologic patients should be considered of paramount importance. However, the wide use of antifungal agents may facilitate the emergence of resistance and may be associated to the occurrence of severe adverse events and eventually may significantly increase the cost of therapeutic procedures. Areas covered: The aim of present review is to analyze advantages and disadvantages of primary antifungal prophylaxis (PAP) in hematologic patients. Expert commentary: Patients with AML/MDS undergoing intensive chemotherapy and patients receiving stem cell transplantation are at high risk of IFI, and therefore may benefit form PAP, although several additional factors should be carefully evaluated in our decision-making approach, including the local epidemiology and the prompt availability of diagnostic facilities. The advent of new treatment options for hematologic patients such as target therapies might facilitate the rise of new risk categories so far underestimated.

Original languageEnglish
Pages (from-to)531-542
Number of pages12
JournalExpert Review of Anti-Infective Therapy
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 3 2018

Fingerprint

Aspergillosis
Hematologic Neoplasms
Antifungal Agents
Mycoses
Stem Cell Transplantation
Therapeutics
Decision Making
Epidemiology
Costs and Cost Analysis
Drug Therapy
Invasive Fungal Infections

Keywords

  • Antifungal prophylaxis
  • drug-drug interactions
  • echinocandins
  • mold-active agents
  • polyenes

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Prophylaxis for aspergillosis in patients with haematological malignancies : pros and cons. / Busca, Alessandro; Pagano, Livio.

In: Expert Review of Anti-Infective Therapy, Vol. 16, No. 7, 03.07.2018, p. 531-542.

Research output: Contribution to journalArticle

@article{981096c8b97d47a9a6ea4a4705436e40,
title = "Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons",
abstract = "Introduction: Along with new diagnostic options, comes the recent development of novel antifungal agents that expanded the spectrum of activity over traditional treatments contributing to the successful management of fungal diseases. Nevertheless, invasive fungal infections (IFI) represent a major hindrance to the favorable outcome of patients with hematologic malignancies. According to these observations, an appropriate prevention of IFI occurring in hematologic patients should be considered of paramount importance. However, the wide use of antifungal agents may facilitate the emergence of resistance and may be associated to the occurrence of severe adverse events and eventually may significantly increase the cost of therapeutic procedures. Areas covered: The aim of present review is to analyze advantages and disadvantages of primary antifungal prophylaxis (PAP) in hematologic patients. Expert commentary: Patients with AML/MDS undergoing intensive chemotherapy and patients receiving stem cell transplantation are at high risk of IFI, and therefore may benefit form PAP, although several additional factors should be carefully evaluated in our decision-making approach, including the local epidemiology and the prompt availability of diagnostic facilities. The advent of new treatment options for hematologic patients such as target therapies might facilitate the rise of new risk categories so far underestimated.",
keywords = "Antifungal prophylaxis, drug-drug interactions, echinocandins, mold-active agents, polyenes",
author = "Alessandro Busca and Livio Pagano",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/14787210.2018.1496329",
language = "English",
volume = "16",
pages = "531--542",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Prophylaxis for aspergillosis in patients with haematological malignancies

T2 - pros and cons

AU - Busca, Alessandro

AU - Pagano, Livio

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Introduction: Along with new diagnostic options, comes the recent development of novel antifungal agents that expanded the spectrum of activity over traditional treatments contributing to the successful management of fungal diseases. Nevertheless, invasive fungal infections (IFI) represent a major hindrance to the favorable outcome of patients with hematologic malignancies. According to these observations, an appropriate prevention of IFI occurring in hematologic patients should be considered of paramount importance. However, the wide use of antifungal agents may facilitate the emergence of resistance and may be associated to the occurrence of severe adverse events and eventually may significantly increase the cost of therapeutic procedures. Areas covered: The aim of present review is to analyze advantages and disadvantages of primary antifungal prophylaxis (PAP) in hematologic patients. Expert commentary: Patients with AML/MDS undergoing intensive chemotherapy and patients receiving stem cell transplantation are at high risk of IFI, and therefore may benefit form PAP, although several additional factors should be carefully evaluated in our decision-making approach, including the local epidemiology and the prompt availability of diagnostic facilities. The advent of new treatment options for hematologic patients such as target therapies might facilitate the rise of new risk categories so far underestimated.

AB - Introduction: Along with new diagnostic options, comes the recent development of novel antifungal agents that expanded the spectrum of activity over traditional treatments contributing to the successful management of fungal diseases. Nevertheless, invasive fungal infections (IFI) represent a major hindrance to the favorable outcome of patients with hematologic malignancies. According to these observations, an appropriate prevention of IFI occurring in hematologic patients should be considered of paramount importance. However, the wide use of antifungal agents may facilitate the emergence of resistance and may be associated to the occurrence of severe adverse events and eventually may significantly increase the cost of therapeutic procedures. Areas covered: The aim of present review is to analyze advantages and disadvantages of primary antifungal prophylaxis (PAP) in hematologic patients. Expert commentary: Patients with AML/MDS undergoing intensive chemotherapy and patients receiving stem cell transplantation are at high risk of IFI, and therefore may benefit form PAP, although several additional factors should be carefully evaluated in our decision-making approach, including the local epidemiology and the prompt availability of diagnostic facilities. The advent of new treatment options for hematologic patients such as target therapies might facilitate the rise of new risk categories so far underestimated.

KW - Antifungal prophylaxis

KW - drug-drug interactions

KW - echinocandins

KW - mold-active agents

KW - polyenes

UR - http://www.scopus.com/inward/record.url?scp=85050533446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050533446&partnerID=8YFLogxK

U2 - 10.1080/14787210.2018.1496329

DO - 10.1080/14787210.2018.1496329

M3 - Article

C2 - 30033822

AN - SCOPUS:85050533446

VL - 16

SP - 531

EP - 542

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 7

ER -